1100 Winter Street
About AMAG Pharmaceuticals
Founded in 1981, AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products.
AMAG currently markets a therapeutic intravenous iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) and an oral rinse for the management of oral mucositis in the United States. To learn more about our products, click here. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers.
Our iron oxide particles are composed of bioavailable iron that is easily absorbed by the body and incorporated into the body's iron stores. As a result, products using our core technology are well suited for use in intravenous iron replacement therapy.
374 articles about AMAG Pharmaceuticals
AMAG Pharmaceuticals Announces the Publication of the PROLONG Trial Evaluating 17-OHPC in the American Journal of Perinatology
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the results of PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) were published online in the American Journal of Perinatology
AMAG Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Friday, November 1, 2019 at 8:00 a.m. ET
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its third quarter 2019 financial results will be released on Friday, November 1, 2019 before the U.S. financial markets open.
Clinical Catch-Up: October 7-11
10/14/2019It was a busy week for clinical trial announcements. Here’s a look.
AMAG Pharmaceuticals Announces the Publication of the Phase 3 Vyleesi™ Data in Obstetrics & Gynecology The RECONNECT Studies Demonstrated a Clinically Meaningful and Statistically Significant Improvement in the Co-Primary Endpoint
AMAG Pharmaceuticals, Inc. announced that the data from its two pivotal, double-blind placebo-controlled Phase 3 trials and its voluntary open-label one year extension studies were published in Obstetrics & Gynecology These publications are currently available online and will appear in the November print issue.
Caligan Partners Issues Letter to AMAG Shareholders
Caligan Partners LP, one of the largest shareholders of AMAG Pharmaceuticals, Inc., issued a letter to AMAG shareholders in connection with its campaign to replace four directors of AMAG.
Caligan Partners Launches Consent Solicitation Process and Sends Letter to AMAG Shareholders
Caligan Partners LP announced that it has mailed a letter to AMAG shareholders in connection with its filing of a definitive consent statement and accompanying form of consent card with the US SEC to allow shareholders to act by written consent to effect the replacement of four directors of AMAG and to, among other things, amend the Company's bylaws to help prevent against entrenchment by incumbent directors.
FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection)
Palatin Technologies, Inc. (NYSE American: PTN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval of AMAG Pharmaceuticals, Inc.'s New Drug Application (NDA) for Vyleesi
June is turning out to be a busy month for approvals for the U.S. Food and Drug Administration. The agency has a slate of PDUFA dates this week, including two for Merck alone. Here’s a look.
It’s a busy week for the U.S. Food and Drug Administration (FDA) with quite a number of pending drug approvals, several of which were delayed for a variety of reasons. Here’s a look.
Shares of AMAG Pharmaceuticals plunged more than 17 percent Friday after the company said its Phase III PROLONG trial of Makena failed to demonstrate a statistically significant difference from placebo in preventing preterm births.
With more than 15 million people in need of anticoagulants around the world, AMAG sees a significant future for ciraparantag.
AMAG Pharmaceuticals and Endoceutics Announce Presentation at the 2018 Annual Meeting of The North American Menopause Society on the Effect of Time Since Menopause, Age and Previous Hormone Therapy on the Response to Intravaginal Prasterone
Study Suggests that While All Postmenopausal Women Benefit from Treatment with Prasterone (INTRAROSA®), Women Experience Greatest Relief of Moderate to Severe Dyspareunia when started on INTRAROSA® within One to Two Years after Menopause
Movers and Shakers Oct. 1
10/1/2018Here's a look at who shook things up in the world of pharma and biotech this week.
AMAG Pharmaceuticals Acquires Orphan Drug Candidate for Treatment of Severe Preeclampsia
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has acquired global rights to develop and market digoxin immune Fab (ovine) (DIF), a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women.
The past few days has had a flurry of activity in the industry with leadership changes. Let's take a look at some of those!
Movers and Shakers for Sept. 4
9/4/2018Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look.
AMAG Pharmaceuticals will secure $530 million in cash as the company divests Cord Blood Registry to GI Partners. Focus will now be on pharmaceutical products.
AMAG PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FILING FOR BREMELANOTIDE
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bremelanotide.
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
Makena was approved by the FDA in February 2011 and remains the first and only FDA-approved treatment option currently available for pregnant women who have had a prior spontaneous preterm birth.